Drug makers accused of hiding clinical data

The editor of the New England Journal of Medicine attacked three of the world's biggest drug companies for "making a mockery" of industry efforts to make clinical trial results more transparent. Dr. Jeffrey Drazen said that as a result, Pfizer, Merck and GlaxoSmithKline could find their studies rejected for publication by major medical journals. The editors of medical journals have been pushing drug companies to register their trials in a public database -- clinicaltrials.gov -- but Dr. Drazen told the Los Angeles Times that the three drug companies are providing "nonsense details" in their reports.

"They are written in a way that they are trying to hide what they are doing." Dr. Drazen added that Eli Lilly and Abbott Laboratories are 90 percent compliant. A spokesperson for Merck said that they were doing "everything they can" to expedite transparency.

- read this story from the Los Angeles Times for more on the remarks

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.